![David Smith](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
David Smith
Director/Board Member at
CODEXIS, INC.
Net worth: 330 268 $ as of 2026-08-30
Profile
Mr. David V.
Smith is an Independent Director at Codexis, Inc. and a Strategic Advisor at Monterey Innovation Acquisition Corp.
He is on the Board of Directors at Acepodia Biotechnologies, Ltd., Neurelis, Inc. and Codexis, Inc. Mr. Smith was previously employed as an Independent Director by IO Biotech, Inc., a Chief Financial Officer & Executive Vice President by Five Prime Therapeutics, Inc., a Chief Operating Officer by IntegenX, Inc., an Independent Director by OncoGenex Pharmaceuticals, Inc., a Chief Financial Officer & Executive Vice President by Thoratec Corp., a CFO, Principal Accounting Officer, VP & Controller by Chiron Corp., a Chief Financial Officer & Vice President-Finance by Anergen, Inc., a Principal by Genentech, Inc., a Principal by International Business Machines Corp., and a Principal by Syntex Corp.
He also served on the board at Acepodia, Inc. (United States) and Perlegen Sciences, Inc. He received his undergraduate degree from Willamette University and an MBA from Golden Gate University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CODEXIS, INC. 0.18% | 2026-06-16 | 194,275 ( 0.18% ) | 330 268 $ | 2026-08-30 |
IO BIOTECH, INC. -.--% | 2025-06-04 | 0 ( -.--% ) | - $ | 2026-08-30 |
David Smith active positions
| Companies | Position | Start |
|---|---|---|
| CODEXIS, INC. | Director/Board Member | 2016-02-29 |
| MONTEREY INNOVATION ACQUISITION CORP. | Corporate Officer/Principal | - |
Acepodia Biotechnologies, Ltd.
 Acepodia Biotechnologies, Ltd. BiotechnologyHealth Technology Develops novel, targeted, allogeneic cell therapies to treat cancers | Director/Board Member | 2022-01-05 |
Neurelis, Inc.
 Neurelis, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes product candidates for the treatment of central nervous system disorders | Director/Board Member | 2021-10-17 |
Former positions of David Smith
| Companies | Position | End |
|---|---|---|
| IO BIOTECH, INC. | Director/Board Member | 2026-03-30 |
| FIVE PRIME THERAPEUTICS, INC. | Director of Finance/CFO | 2021-04-15 |
IntegenX, Inc.
 IntegenX, Inc. BiotechnologyHealth Technology Develops rapid human DNA identification technology, next-gen sequencing library preparation, and DNA/RNA ambient temperature stability and storage products | Chief Operating Officer | 2018-02-28 |
| THORATEC CORPORATION | Director of Finance/CFO | 2011-06-30 |
Training of David Smith
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
83
1st degree connections
17
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 17 |
|---|---|
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Health Technology |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
International Business Machines Corp.
 International Business Machines Corp. Information Technology ServicesTechnology Services Provides software, IT consulting, cloud and infrastructure services | Technology Services |
Syntex Corp.
 Syntex Corp. Pharmaceuticals: MajorHealth Technology Pharmaceutical concern | Health Technology |
Anergen, Inc.
 Anergen, Inc. BiotechnologyHealth Technology Develops propriety therapeutics designed to interrupt the antigen process | Health Technology |
Thoratec Corp.
 Thoratec Corp. Medical SpecialtiesHealth Technology Manufactures and distributes circulatory support devices for heart failure patients | Health Technology |
Perlegen Sciences, Inc.
 Perlegen Sciences, Inc. Drugstore ChainsRetail Trade Discovers and develops drugs | Retail Trade |
Codexis, Inc.
 Codexis, Inc. Chemicals: SpecialtyProcess Industries Develops biocatalytic chemical processes | Process Industries |
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops protein therapeutics for cancer and inflammatory diseases | Health Technology |
IntegenX, Inc.
IntegenX, Inc. BiotechnologyHealth Technology Develops rapid human DNA identification technology, next-gen sequencing library preparation, and DNA/RNA ambient temperature stability and storage products | Health Technology |
Golden Gate University
 Golden Gate University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Willamette University
 Willamette University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OncoGenex Pharmaceuticals, Inc.
 OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapies that address treatment resistance in cancer patients | Health Technology |
Neurelis, Inc.
Neurelis, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes product candidates for the treatment of central nervous system disorders | Health Technology |
Acepodia Biotechnologies, Ltd.
Acepodia Biotechnologies, Ltd. BiotechnologyHealth Technology Develops novel, targeted, allogeneic cell therapies to treat cancers | Health Technology |
Monterey Innovation Acquisition Corp.
 Monterey Innovation Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
IO Biotech, Inc.
 IO Biotech, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel, immune-modulating cancer therapies | Health Technology |
- Stock Market
- Insiders
- David Smith
